Intellia Therapeutics extended support for its CRISPR portfolio in hereditary angioedema after a second positive Phase III data release in two months. The company’s lonvoguran ziclumeran (lonvo-z) in the pivotal HAELO study (NCT06634420) met additional secondary endpoints, reinforcing the primary efficacy signal previously reported. According to the reported readouts, lonvo-z continued to show reductions in attack frequency metrics and improvements in AE-QoL over Weeks 5–28 and through Week 28 observations. Intellia said the data underpin continued Biologics License Application (BLA) work that began in April, with plans to complete the filing by year-end and pursue FDA approval in the first half of 2027. The update reflects how incremental clinical evidence can drive investor confidence during rolling regulatory pathways, especially in gene-editing programs where durable outcomes are a key differentiator.